Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340984 | 0.85 | ARG1 (0.36) | ARG1ARG2MEN1KMT2ACYP2D6 | |
| SCHEMBL6547926 | 0.84 | MEN1 (0.37) | TSHRARG1ARG2MEN1KMT2A | |
| SCHEMBL18985191 | 0.77 | CYP2D6 (0.33) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7435814 | 0.77 | MGAM (0.34) | TSHRARG1ARG2MEN1KMT2A | |
| SCHEMBL7338385 | 0.75 | ARG1 (0.35) | ARG1ARG2 | |
| SCHEMBL7338721 | 0.75 | ARG1 (0.35) | ARG1ARG2 | |
| SCHEMBL7339530 | 0.74 | TDP1 (0.39) | TSHRMEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL7340979 | 0.74 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL7349345 | 0.74 | SLC1A3 (0.35) | TSHRARG1ARG2 | |
| SCHEMBL27503472 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901775-B1 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1901775-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | Jerini AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003411-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2007-01-11 | — | — | WO | disclosed |
| EP-1741444-A1 | Kinin antagonists for treating bladder dysfunction | Jerini AG (DE) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | TSHR 1755/4885ARG1 968/4885ARG2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.